NCT06846684View on ClinicalTrials.gov

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions

Drug Drug Interaction (DDI)

Interventions

DRUG

SB17170

PO, QD

DRUG

SB_MDZ

IV

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

SPARK Biopharma

All Listed Sponsors

lead

SPARK Biopharma

INDUSTRY

NCT06846684 - A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects | Biotech Hunter | Biotech Hunter